This study demonstrated that adding vistusertib (mTOR inhibitor) to anastrozole improved the progression-free rate at 8 weeks (8wk-PFR), overall response rate, and PFS for patients with endometrial cancer and had manageable adverse events [31]. Here, MTOR is linked to endometrial cancer.